Trials Closed to Accrual
SARC003: Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma
PI: Elizabeth Fox, MD and Shreyas Patel, MD
Date Initiated: 5/05/2005
SARC003 on www.ClinicalTrials.gov
SARC004: Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
PI: Scott Schuetze, MD, PhD
Date Initiated: 4/21/2005
SARC004 on www.ClinicalTrials.gov
SARC005: Adjuvant Treatment of High Risk Uterine Leiomyosarcoma with Gemcitabine/Docetaxel followed by Doxorubicin: Phase II Trial
PI: Martee L Hensley, MD
Date Initiated: 1/28/2006
SARC005 on www.ClinicalTrials.gov
SARC007: A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas
PI: Dejka M. Araujo, MD
Date Initiated: 6/21/2006
SARC007 on www.ClinicalTrials.gov
Closed SARC Trials
SARC001: Phase II Trial if Imatinib Mesylate (Gleevec) in Patients with Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial
PI: Dr. Laurence Baker, DO
Date Initiated: 11/12/2001
Date closed to accrual: 6/9/2005
SARC 002: Phase III Randomized Trial of 120-minute infusion Gemcitabine v. 90-minute infusion Gemcitabine plus Docetaxal in unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society
PI: Robert Maki, MD PhD
Date Initiated: 1/2/2003
Date Terminated: 4/17/2007